Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Jude Onyia Sells 2,331 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares of the company’s stock, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Neurocrine Biosciences Stock Performance

NBIX opened at $125.44 on Wednesday. The company has a market cap of $12.70 billion, a PE ratio of 33.63 and a beta of 0.34. The stock has a 50-day moving average of $119.60 and a 200-day moving average of $131.25. Neurocrine Biosciences, Inc. has a 52-week low of $110.95 and a 52-week high of $157.98.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. raised their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Barclays reduced their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Raymond James reiterated an “outperform” rating and issued a $155.00 target price on shares of Neurocrine Biosciences in a report on Thursday, October 10th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, Jefferies Financial Group upped their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a report on Monday, August 19th. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $163.91.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its stake in shares of Neurocrine Biosciences by 34.1% in the second quarter. GAMMA Investing LLC now owns 1,553 shares of the company’s stock worth $214,000 after buying an additional 395 shares during the last quarter. First Hawaiian Bank raised its holdings in Neurocrine Biosciences by 6.2% in the 2nd quarter. First Hawaiian Bank now owns 5,483 shares of the company’s stock worth $755,000 after acquiring an additional 320 shares during the period. Massmutual Trust Co. FSB ADV lifted its position in Neurocrine Biosciences by 43.4% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 512 shares of the company’s stock worth $70,000 after acquiring an additional 155 shares during the last quarter. Park Avenue Securities LLC boosted its holdings in Neurocrine Biosciences by 3.8% during the second quarter. Park Avenue Securities LLC now owns 9,933 shares of the company’s stock valued at $1,367,000 after acquiring an additional 363 shares during the period. Finally, CWM LLC grew its position in shares of Neurocrine Biosciences by 46.8% in the second quarter. CWM LLC now owns 6,849 shares of the company’s stock valued at $943,000 after purchasing an additional 2,185 shares during the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.